Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis.
Brand SR, Degenhardt TP, Person K, Sobel JD, Nyirjesy P, Schotzinger RJ, Tavakkol A. Brand SR, et al. Am J Obstet Gynecol. 2018 Jun;218(6):624.e1-624.e9. doi: 10.1016/j.ajog.2018.03.001. Epub 2018 Mar 11. Am J Obstet Gynecol. 2018. PMID: 29534874 Clinical Trial.
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of VT-1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail.
Elewski B, Brand S, Degenhardt T, Curelop S, Pollak R, Schotzinger R, Tavakkol A. Elewski B, et al. Br J Dermatol. 2021 Feb;184(2):270-280. doi: 10.1111/bjd.19224. Epub 2020 Jul 13. Br J Dermatol. 2021. PMID: 32421854 Clinical Trial.
Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections.
Martens MG, Maximos B, Degenhardt T, Person K, Curelop S, Ghannoum M, Flynt A, Brand SR. Martens MG, et al. Among authors: brand sr. Am J Obstet Gynecol. 2022 Dec;227(6):880.e1-880.e11. doi: 10.1016/j.ajog.2022.07.023. Epub 2022 Jul 19. Am J Obstet Gynecol. 2022. PMID: 35863457 Free article. Clinical Trial.
The Fungal Cyp51 Inhibitor VT-1129 Is Efficacious in an Experimental Model of Cryptococcal Meningitis.
Wiederhold NP, Najvar LK, Garvey EP, Brand SR, Xu X, Ottinger EA, Alimardanov A, Cradock J, Behnke M, Hoekstra WJ, Schotzinger RJ, Jaramillo R, Olivo M, Kirkpatrick WR, Patterson TF. Wiederhold NP, et al. Among authors: brand sr. Antimicrob Agents Chemother. 2018 Aug 27;62(9):e01071-18. doi: 10.1128/AAC.01071-18. Print 2018 Sep. Antimicrob Agents Chemother. 2018. PMID: 29987152 Free PMC article.
In Vivo Efficacy of VT-1129 against Experimental Cryptococcal Meningitis with the Use of a Loading Dose-Maintenance Dose Administration Strategy.
Wiederhold NP, Xu X, Wang A, Najvar LK, Garvey EP, Ottinger EA, Alimardanov A, Cradock J, Behnke M, Hoekstra WJ, Brand SR, Schotzinger RJ, Jaramillo R, Olivo M, Kirkpatrick WR, Patterson TF. Wiederhold NP, et al. Among authors: brand sr. Antimicrob Agents Chemother. 2018 Oct 24;62(11):e01315-18. doi: 10.1128/AAC.01315-18. Print 2018 Nov. Antimicrob Agents Chemother. 2018. PMID: 30104280 Free PMC article.
The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii.
Lockhart SR, Fothergill AW, Iqbal N, Bolden CB, Grossman NT, Garvey EP, Brand SR, Hoekstra WJ, Schotzinger RJ, Ottinger E, Patterson TF, Wiederhold NP. Lockhart SR, et al. Among authors: brand sr. Antimicrob Agents Chemother. 2016 Mar 25;60(4):2528-31. doi: 10.1128/AAC.02770-15. Print 2016 Apr. Antimicrob Agents Chemother. 2016. PMID: 26787697 Free PMC article.
37 results